(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...

The pharmaceutical company Amgen announced Wednesday that it will decrease the price of its cholesterol lowering drug Repatha by 60%. The company said some patients weren't filling their prescriptions ...

Amgen has been trying since 2015 to protect its PCSK9 cholesterol drug Repatha by keeping Sanofi and Regeneron’s rival Praluent off the market, even going as far as to ask the U.S. Supreme Court to ...

To view the multimedia assets associated with this press release, please click: http://www.multivu.com/players/English/7414052-amgen-repatha/. The EC approved Repatha ...

Amgen cut the price of its cholesterol drug Repatha by 60%. The drug used to have a list price of more than $14,000 a year. Now, it'll be $5,850 a year. The goal is to make the drug more affordable to ...

(Reuters) - Amgen Inc , looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the biotechnology company said on Wednesday.